Clinical and biological aspects of myeloid leukemia in Down syndrome

Area of Science:

• Pediatric Oncology
• Hematology
• Genetics

Background:

• Children with Down syndrome (DS) have a significantly increased risk of developing myeloid leukemia (ML-DS).
• Transient abnormal myelopoiesis (TAM), a condition involving the expansion of fetal liver-derived megakaryocyte progenitors, often precedes ML-DS and is typically self-limiting.
• Significant progress has been made in understanding the genetic landscape of ML-DS, with GATA1 mutations identified in nearly all cases of TAM and ML-DS.

Purpose of the Study:

• To highlight the current understanding of myeloid leukemia in Down syndrome (ML-DS) and its precursor, transient abnormal myelopoiesis (TAM).
• To emphasize the effectiveness of reduced-intensity chemotherapy in treating ML-DS.
• To identify the knowledge gap concerning the mechanisms and treatment strategies for leukemia relapse in children with Down syndrome.

Main Methods:

• Review of international studies and clinical data on ML-DS and TAM.
• Analysis of genetic and epigenetic findings related to GATA1 mutations in these conditions.
• Synthesis of current treatment consensus and identification of areas requiring further research.

Main Results:

• Reduced-intensity chemotherapy has led to excellent outcomes for ML-DS.
• GATA1 mutations are a hallmark of both TAM and ML-DS.
• Despite advances, the mechanisms driving relapse in ML-DS are largely unknown.

Conclusions:

• While ML-DS is treatable with current chemotherapy regimens, relapse presents a critical challenge with poor outcomes and no established treatment guidelines.
• Further research is urgently needed to elucidate the mechanisms of relapse in pediatric myeloid leukemia in Down syndrome.
• Focusing on relapse is essential for improving the long-term prognosis for these young patients.